Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Deggingen – page 107

1 295 clinical trials in Deggingen, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Deggingen at a glance
1 295
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 295 trials in Deggingen

Open in trial search

Conjunctivitis allergic+1

Not recruiting

Study on the Effects of Mannan-Conjugated Birch Pollen Allergoids for Adolescents and Adults with Birch Pollen-Induced Allergic Rhinitis or Rhinoconjunctivitis

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Bilastine
  • Sponsor:Inmunotek S.L.

Study on the Effects of Latozinemab for Patients with Frontotemporal Dementia Due to Progranulin Gene Mutations

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Latozinemab
  • Sponsor:Alector LLC

Study on the Effectiveness of Bortezomib, Rituximab, and Ibrutinib for Patients with Newly Diagnosed Waldenström’s Macroglobulinemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Universitaetsklinikum Ulm AöR

Study on Venetoclax, Cytarabine, and Mitoxantrone for Adults with Relapsed or Refractory Acute Myeloid Leukemia (AML) Eligible for Intensive Treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cytarabine
  • Sponsor:Technische Universitat Dresden

Acute myeloid leukaemia+1

Not recruiting

Study Comparing CPX-351 and Conventional Drug Combination for Patients with High-Risk Myelodysplastic Syndromes and Oligoblastic Acute Myeloid Leukemia Before Stem Cell Transplant

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:GWT-Tud GmbH

Chondrosarcoma

Not recruiting

Study of INBRX-109 (ozekibart) compared to placebo in adults with unresectable or metastatic chondrosarcoma - a rare bone cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Acetylcysteine
  • Sponsor:Inhibrx Biosciences Inc.

Study on Talazoparib and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Enzalutamide
  • Sponsor:Pfizer Inc.

Multiple sclerosis

Not recruiting

Study on the Effectiveness and Safety of Frexalimab and Teriflunomide in Adults with Relapsing Multiple Sclerosis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Colestyramine
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study of Tucidinostat and Nivolumab for Patients with Advanced Melanoma Not Treated with PD-1 or PD-L1 Inhibitors

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Huyabio International LLC

Study on Brigatinib, Ceritinib, and Alectinib for Patients with Advanced ALK+ Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Alectinib
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Evaluation of clonidine and doxazosin for treating nightmares in adults with Post-traumatic Stress Disorder

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Doxazosin
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

Study Comparing ONC-392 and Docetaxel for Patients with Metastatic Non-Small Cell Lung Cancer After PD-1/PD-L1 Inhibitor Treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Oncoc4 Inc.

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Deggingen

What the registry says about research in the country

01 Cardiovascular Research

Innovative studies focusing on heart failure prevention and managing atrial fibrillation, exploring new therapeutic approaches for cardiac conditions.

  • Heart Failure Prevention Studies
  • Cardioembolic Event Prevention
  • Blood Pressure Management

Research includes evaluation of novel drug combinations and preventive therapies for cardiovascular outcomes.

02 Metabolic Disorders

Comprehensive research on hypertriglyceridemia and Type 2 Diabetes Mellitus, testing new treatments for metabolic conditions.

  • Triglyceride Level Management
  • Diabetes Cardiovascular Outcomes
  • Metabolic Disease Therapies

Studies aim to improve treatment options and long-term patient outcomes in metabolic disorders.

03 Respiratory Medicine

Advanced research targeting Chronic Obstructive Pulmonary Disease, investigating new therapeutic approaches for respiratory conditions.

  • COPD Exacerbation Management
  • Respiratory Disease Treatment
  • Long-term Disease Control

Focus on reducing acute exacerbations and improving quality of life for COPD patients.

04 Other Therapeutic Areas

Studies addressing gout with hyperuricemia and various forms of hypertension, developing targeted treatments.

  • Uric Acid Management
  • Resistant Hypertension Studies
  • Long-term Safety Evaluations

Research aimed at developing effective treatments for complex medical conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.